Context Therapeutics (NASDAQ:CNTX – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.11), Zacks reports.
Context Therapeutics Stock Performance
Context Therapeutics stock traded down $0.14 during midday trading on Friday, reaching $1.95. The stock had a trading volume of 339,093 shares, compared to its average volume of 309,652. The stock has a market capitalization of $146.25 million, a P/E ratio of -2.14 and a beta of 2.25. The firm’s fifty day simple moving average is $2.09 and its 200-day simple moving average is $2.06. Context Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.75.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Context Therapeutics in a research report on Monday, September 23rd.
Context Therapeutics Company Profile
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Recommended Stories
- Five stocks we like better than Context Therapeutics
- Investing in Travel Stocks Benefits
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- Profitably Trade Stocks at 52-Week Highs
- MarketBeat Week in Review – 11/4 – 11/8
- What is the FTSE 100 index?
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
